Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT03922724 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

330

Enrollment

NIH

Sponsor class

Conditions

Peripheral T-cell Lymphomas
Lymphoproliferative Disorders
Immune System Diseases

Interventions

DRUG: ATL-RIC
DRUG: mRIC
PROCEDURE: allo HCT
DRUG: RIC
DRUG: GVHD prophylaxis
DRUG: IOC

Sponsor

National Cancer Institute (NCI)